NanoString Technologies

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications.

NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

NanoString Technologies headquartered in United States, North America, operates in the Biotechnology, Medical, Health Diagnostics sector. The company focuses on Biotechnology and has secured $178.3B in funding across 204 round(s). With a team of 251-500 employees, NanoString Technologies is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - NanoString Technologies, raised $30.0M. Discover more about their projects, partnerships, and impact on our platform.